Regeneron Pharmaceuticals, Inc. (REGN)

NasdaqGS - NasdaqGS Delayed Price. Currency in USD
395.22-4.16 (-1.04%)
At close: 4:00 PM EDT
People also watch:
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
Prev Close399.38
Bid378.01 x 200
Ask410.00 x 100
Day's Range394.42 - 402.36
52wk Range329.09 - 592.59
1y Target EstN/A
Market Cap42.41B
P/E Ratio (ttm)61.66
Avg Vol (3m)822,492
Dividend & YieldN/A (N/A)
Earnings DateN/A
Trade prices are not sourced from all markets
  • Barrons.comyesterday

    [$$] Regeneron Can Generate Big Returns for Investors

    This past year has been tough for Regeneron Pharmaceuticals. Regeneron (REGN) today released positive data from a late stage study of its closely watched cholesterol-lowering drug Praluent. The biotech giant announced that adding the injectable drug to existing treatment reduced so-called “bad cholesterol” by 50% in patients with an inherited form of high cholesterol, and reduced the need for an expensive procedure that removes the dangerous fats from a patient’s blood.

  • TheStreet.comyesterday

    How Will Regeneron (REGN) Stock React to Cholesterol Drug Trial Success?

    Regeneron Pharmaceuticals (REGN) and Sanofi (SNY) said today that trials of their cholesterol drug Praulent met targets.

  • Regeneron/Sanofi Present Positive Phase III Praluent Data
    Zacks2 days ago

    Regeneron/Sanofi Present Positive Phase III Praluent Data

    Regeneron Pharmaceuticals (REGN) and Sanofi presented positive phase III data on Praluent in patients who underwent LDL apheresis therapy.